Atea Prescription drugs’ COVID-19 remedy picture illustration
Dado Ruvic | Reuters
A mid-stage trial testing Atea Pharmaceuticals‘ Covid-19 remedy failed to fulfill the principle objective of decreasing the quantity of SARS-CoV-2 virus in non-hospitalized sufferers with delicate or average illness, the corporate mentioned on Tuesday.
Atea’s shares slumped 70.9% to $11.78 in premarket buying and selling.
The corporate is creating the oral drug, AT-527, in partnership with Roche and each the businesses are collaborating on a number of research of the drug for the remedy of Covid-19.
Within the mid-stage examine, AT-527 didn’t present a transparent discount in SARS-CoV-2 viral load within the general inhabitants of sufferers with delicate or average Covid-19 in comparison with placebo, however it confirmed a discount in viral load in high-risk sufferers with underlying well being circumstances.
Many elements together with completely different variants rising throughout the examine, higher penetration of vaccinations inside the enrolled inhabitants might have impacted outcomes, it mentioned.
Atea mentioned based mostly on the newest outcomes and the evolving Covid-19 surroundings, it’s modifying an ongoing late-stage examine testing the drug in non-hospitalized sufferers with delicate to average Covid-19 to incorporate modifications to the trial’s major objective and affected person inhabitants.
Because of this, the corporate now expects late-stage trial information within the second half of 2022, as a substitute of the latter half of this yr.
